Type 2 diabetes is the most common form of diabetes in humans. It results from a combination of factors that impair beta-cell function and tissue insulin sensitivity. However, growing evidence is showing that the beta-cell is central to the development and progression of this form of diabetes. Reduced islet and/or insulin-containing cell mass or volume in Type 2 diabetes has been reported by several authors. Furthermore, studies with isolated Type 2 diabetic islets have consistently shown both quantitative and qualitative defects of glucose-stimulated insulin secretion. The impact of genotype in affecting beta-cell function and survival is a very fast growing field or research, and several gene polymorphisms have been associated with this form of diabetes. Among acquired factors, glucotoxicity, lipotoxicity and altered IAPP processing are likely to play an important role. Interestingly, however, pharmacological intervention can improve several defects of Type 2 diabetes islet cells in vitro, suggesting that progression of the disease might not be relentless.

Marchetti, P., Dotta, F., Lauro, D., Purrello, F. (2008). An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. REGULATORY PEPTIDES, 146(1-3), 4-11 [10.1016/j.regpep.2007.08.017].

An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment

LAURO, DAVIDE;
2008-02-07

Abstract

Type 2 diabetes is the most common form of diabetes in humans. It results from a combination of factors that impair beta-cell function and tissue insulin sensitivity. However, growing evidence is showing that the beta-cell is central to the development and progression of this form of diabetes. Reduced islet and/or insulin-containing cell mass or volume in Type 2 diabetes has been reported by several authors. Furthermore, studies with isolated Type 2 diabetic islets have consistently shown both quantitative and qualitative defects of glucose-stimulated insulin secretion. The impact of genotype in affecting beta-cell function and survival is a very fast growing field or research, and several gene polymorphisms have been associated with this form of diabetes. Among acquired factors, glucotoxicity, lipotoxicity and altered IAPP processing are likely to play an important role. Interestingly, however, pharmacological intervention can improve several defects of Type 2 diabetes islet cells in vitro, suggesting that progression of the disease might not be relentless.
7-feb-2008
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/13 - ENDOCRINOLOGIA
Settore MED/09 - MEDICINA INTERNA
Settore MED/50 - SCIENZE TECNICHE MEDICHE APPLICATE
English
Con Impact Factor ISI
Hypoglycemic Agents; Fatty Acids, Nonesterified; Insulin-Secreting Cells; Cell Count; Humans; Metformin; Diabetes Mellitus, Type 2; Insulin
Marchetti, P., Dotta, F., Lauro, D., Purrello, F. (2008). An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. REGULATORY PEPTIDES, 146(1-3), 4-11 [10.1016/j.regpep.2007.08.017].
Marchetti, P; Dotta, F; Lauro, D; Purrello, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/41910
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 89
  • ???jsp.display-item.citation.isi??? 86
social impact